{
    "organizations": [],
    "uuid": "8b1dc8f379a150ab7bc7fd980b5933c01307db74",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cantargia-proceedings-concerning-c/brief-cantargia-proceedings-concerning-cantargias-patent-for-hematological-cancers-cancelled-idUSFWN1PH07Q",
    "ord_in_thread": 0,
    "title": "BRIEF-Cantargia: Proceedings Concerning Cantargia's Patent For Hematological Cancers Cancelled",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 22 (Reuters) - CANTARGIA AB:\n* EUROPEAN PATENT OFFICE CANCELS ORAL OPPOSITION PROCEEDINGS CONCERNING CANTARGIA‘S PATENT FOR HEMATOLOGICAL CANCERS\n* ‍CANTARGIA‘S PATENT PROTECTION IN EUROPE IS EXPECTED TO REMAIN ESSENTIALLY UNCHANGED​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-22T18:06:00.000+02:00",
    "crawled": "2018-01-23T18:16:13.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "cantargia",
        "ab",
        "european",
        "patent",
        "office",
        "cancel",
        "oral",
        "opposition",
        "proceeding",
        "concerning",
        "cantargia",
        "patent",
        "hematological",
        "cancer",
        "patent",
        "protection",
        "europe",
        "expected",
        "remain",
        "essentially",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}